Perrigo Co Plc - Company Profile

Powered by

All the data and insights you need on Perrigo Co Plc in one report.

  • Save hours of research time and resources with
    our up-to-date Perrigo Co Plc Strategy Report

  • Understand Perrigo Co Plc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Perrigo Co Plc (Perrigo) is an over-the-counter consumer goods and specialty pharmaceutical company. It develops, manufactures and distributes over-the-counter products, generic, specialty pharmaceutical company, nutritional products, and infant formulas and foods. The company’s major products include analgesics, gastrointestinal, personal care and derma therapeutics, clobetasol spray, clindamycin foam, mupirocin ointment, Ketoconazole, halobetasol ointment and cream and permethrin cream. It markets products through wholesalers, retail drugs, supermarket and mass merchandise chains and direct sales representatives. The company has operational presence in various geographical regions such as Australia, Israel and China. Perrigo is headquartered in Dublin, Ireland.

Gain a 360-degree view of Perrigo Co Plc and make more informed decisions for your business Gain a 360-degree view of Perrigo Co Plc and make more informed decisions for your business Find out more
Headquarters Ireland

Address The Sharp Building, Hogan Place, Dublin 2, D02TY74


Telephone 353 1 7094000

No of Employees 9,140

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange PRGO (NYSE)

Revenue (2022) $4.7B 4.6% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ 91% (2022 vs 2021)

Market Cap* $4.1B

Net Profit Margin (2022) XYZ 91.5% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Perrigo Co Plc premium industry data and analytics

390+

Marketed Drugs

Understand Perrigo Co Plc’s commercialized product portfolio to stay one step ahead of the market.

120+

Clinical Trials

Determine Perrigo Co Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

40+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

30+

Pipeline Drugs

Identify which of Perrigo Co Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Catalyst Calendar

Proactively evaluate Perrigo Co Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Perrigo Co Plc (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Perrigo Co Plc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Analgesics Advil
Antacids/anti-gas Products Afrin
Anti-Diarrheal Products Alavert
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Perrigo Co Plc portfolio and identify potential areas for collaboration Understand Perrigo Co Plc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In April, the company's Opill entered into a partnership with the Women's National Basketball Association to expand health education.
2023 Others In August, Perrigo and Mead Johnson Nutrition secured the US FDA warning letters for baby formula.
2023 Regulatory Approval In July, the company received the US FDA approval for Opill, a progestin-only daily oral contraceptive, for over-the-counter use for all ages.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Perrigo Co Plc Johnson & Johnson The Procter & Gamble Co Pfizer Inc Bayer AG
Headquarters Ireland United States of America United States of America United States of America Germany
City Dublin New Brunswick Cincinnati New York Leverkusen
State/Province - New Jersey Ohio New York Nordrhein-Westfalen
No. of Employees 9,140 131,900 107,000 88,000 99,723
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Rolf A. Classon Chairman Executive Board 2017 -
Patrick Lockwood-Taylor Director; President; Chief Executive Officer Executive Board 2023 -
Thomas M. Farrington Executive Vice President; Chief Information Officer Senior Management 2015 -
Grainne Quinn Executive Vice President; Chief Medical Officer Senior Management 2016 -
Alison Ives Chief Scientific Officer; Executive Vice President Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Perrigo Co Plc key executives to enhance your sales strategy Gain insight into Perrigo Co Plc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward